PAOG Sets 2021 Cannabis Biopharmaceutical Revenue Goals
News provided by
Share this article
Share this article
SANDUSKY, OH, Jan. 14, 2021 /PRNewswire/ PAO Group, Inc. (USOTC: PAOG) today published a management outlook for 2021 on the company s strategy to develop and monetize the cannabis assets acquired last year. The strategic outlook is included in its entirety below:
PAOG 2021 Cannabis Biopharmaceutical Strategic Outlook
PAOG is a longtime participant in the cannabis sector working on initiatives to introduce cannabis treatments as alternatives to traditional pharmaceuticals, particularly where existing pharmaceutical treatments have potentially severe secondary ramifications as is the case with opioid based treatments.
Last year, the company shifted its primary focus to the development biopharmaceutical treatments derived from cannabis.
PAO Group, Inc.: PAOG Publishes 2021 Cannabis Biopharmaceutical Strategic Outlook
Sandusky, Ohio (Newsfile Corp. - January 14, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today published a management outlook for 2021 on the company s strategy to develop and monetize the cannabis assets acquired last year. The strategic outlook is included in its entirety below:
PAOG 2021 Cannabis Biopharmaceutical Strategic Outlook
PAOG is a longtime participant in the cannabis sector working on initiatives to introduce cannabis treatments as alternatives to traditional pharmaceuticals, particularly where existing pharmaceutical treatments have potentially severe secondary ramifications as is the case with opioid based treatments.
Last year, the company shifted its primary focus to the development biopharmaceutical treatments derived from cannabis.
PAO Group, Inc.: PAOG Develops CBD Nutraceutical for $12.7 Billion from Patented Extract Process
Sandusky, Ohio (Newsfile Corp. - December 18, 2020) - PAO Group, Inc. (OTC Pink: PAOG) today announced the company expects to generate its first revenue next year in 2021 from its Cannabidiol (CBD) extraction technology, RespRx, acquired in July of this year, 2020.
Yesterday, PAOG announced an engagement with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary CBD extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
PAOG, through its engagement with PRCCI, expects to rapidly produce its CBD COPD Nutraceutical product and establish sales. Grand View Research forecasts the CBD Nutraceutical marketplace reaching a value of $12.7 billion by 2025.
PAOG Announces Puerto Rico Consortium For Clinical Investigation Engagement To Advance CBD COPD Nutraceutical Care Solution marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SANDUSKY, Ohio, Dec. 18, 2020 /PRNewswire/ PAO Group, Inc. (USOTC: PAOG) today announced the company expects to generate its first revenue next year in 2021 from its Cannabidiol (CBD) extraction technology, RespRx, acquired in July of this year, 2020.
Yesterday, PAOG announced an engagement with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary CBD extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
PAOG, through its engagement with PRCCI expects to rapidly produce its CBD COPD Nutraceutical product and establish sales. Grand View Research forecasts the CBD Nutraceutical marketplace reaching a value of $12.7 billion by 2025.